Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

This is the 11th year that Little Eric’s Foundation participated, as an organization, in Cycle for Survival in New York City.

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

The community has a GoFundMe campaign that is raising money for the cancer treatment for longtime Brookfield firefighter ...

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Triplet therapy with bortezomib, lenalidomide and dexamethasone — a regimen often referred to as VRd — is a current standard ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...